$XBI $93.55 | +4.28%
Covid Updates
$BNTX +3.6% & $PFE -1.0% Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older. source
$MRNA Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273. source
Pipeline Updates
$CHRS +4.4% Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event. source
$SGMO +9.6% Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation. source
$APVO 0.0% Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia. source
$URGN +7.2% UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer. source
$MDWD +5.4% MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022. source
$ALDX -2.9% Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day. source
$LNTH +8.4% Novartis will include PYLARIFY® (piflufolastat F18) in their clinical trials for Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) for the selection of patients with prostate cancer. source
$VBIV +10.1% VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults. source
$AGLE +2.2% Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting. source
$VECT -1.4% VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference. source
$LPCN -20.3% LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™. source
$TSHA +4.8% Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome. source
$ZNTL +6.5% Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3. source
$ENTA +3.4% Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19. source
$IMGN +11.7% ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer. source
Business Updates
$CALA -5.1% Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common
Stock and Warrants to Purchase Common Stock source
$GERN +5.8% Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants source
$SLNO -22.8% Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering. source
$IGMS +96.7% Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology, and Inflammation Targets. source
Posted by FS/JM
Komentarji